Breaking News To Trading Moves
The Allogeneic Pivot: Reshaping the CAR-T Market Landscape
Allogene Therapeutics experienced a stock increase of over 55% following positive mid-stage trial data for its CAR-T therapy, which showed a reduced risk of relapse in blood cancer patients. This development suggests a potential market shift favoring allogeneic, off-the-shelf…